Jahnabi Hazarika

Title: Jahnabi Hazarika: Innovator in CRISPR Technology

Introduction

Jahnabi Hazarika is a prominent inventor based in Bengaluru, India. He has made significant contributions to the field of biotechnology, particularly in the application of CRISPR technology. With a total of 3 patents to his name, Hazarika is at the forefront of innovative research that has the potential to transform therapeutic approaches.

Latest Patents

Hazarika's latest patents include groundbreaking work on the DNA-binding domain of the CRISPR system. One of his notable inventions focuses on non-fucosylated and partially fucosylated proteins, along with methods for obtaining cells with modified fucosylation pathways. This method leads to the production of partially fucosylated and non-fucosylated protein products, specifically antibodies. The technology targets the Fut8 gene and GMD gene in a cell, which is crucial for developing therapeutics and biomarkers, as well as for diagnosing and prognosing diseases. Another significant patent involves methods for obtaining afucosylated proteins, utilizing CRISPR technology in a protein-producing cell line. The resulting monoclonal antibody is completely afucosylated, demonstrating a higher degree of antibody-dependent cellular cytotoxicity.

Career Highlights

Hazarika is currently associated with Zumutor Biologics Inc., where he continues to push the boundaries of biotechnological research. His work is instrumental in advancing the understanding and application of CRISPR technology in the production of therapeutic proteins.

Collaborations

Some of his notable coworkers include Bhargav Prasad and Divya Unnikrishnan, who contribute to the innovative environment at Zumutor Biologics Inc. Their collaborative efforts enhance the research and development capabilities of the organization.

Conclusion

Jahnabi Hazarika is a visionary inventor whose work in CRISPR technology is paving the way for new therapeutic solutions. His contributions to biotechnology are significant and hold promise for future advancements in the field.